Courtesy of Roche
Vacaville, Calif.
Lonza is investing $1.2 billion to purchase a pharmaceutical manufacturing campus in Vacaville, Calif. Presently occupied by Genentech, a subsidiary of Roche, the 427,000-sf complex provides a total bioreactor capacity of approximately 330 liters. Lonza is offering employment to 750 personnel at the site, which will continue to supply its current products at a committed volume of 30 percent throughout 2025. As the plant transitions to serve alternative customers, an investment of $550 million will upgrade and enhance existing capabilities to support the next generation of mammalian biological therapies.
Source
